Drug Profile
Research programme: allosteric Akt inhibitors - Almac Discovery
Latest Information Update: 20 Jul 2017
Price :
$50
*
At a glance
- Originator Almac Discovery
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Jul 2017 Discontinued - Preclinical for Cancer in United Kingdom (Almac discovery communication and pipeline, July 2017)
- 20 Dec 2012 Preclinical trials in Cancer in United Kingdom (unspecified route)